Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease
BACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published by the Canadian Association of Gastroenterology in 2004. However, recent clinical findings and drug developments warrant a review and update of these guidelines.
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2009/201430 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550054095749120 |
|---|---|
| author | Daniel C Sadowski Charles N Bernstein Alain Bitton Ken Croitoru Richard N Fedorak Anne Griffiths the CAG Crohn’s Consensus Group |
| author_facet | Daniel C Sadowski Charles N Bernstein Alain Bitton Ken Croitoru Richard N Fedorak Anne Griffiths the CAG Crohn’s Consensus Group |
| author_sort | Daniel C Sadowski |
| collection | DOAJ |
| description | BACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published by the Canadian Association of Gastroenterology in 2004. However, recent clinical findings and drug developments warrant a review and update of these guidelines. |
| format | Article |
| id | doaj-art-316987c9b5fa442f9243dea3d0252db9 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-316987c9b5fa442f9243dea3d0252db92025-02-03T06:07:48ZengWileyCanadian Journal of Gastroenterology0835-79002009-01-0123318520210.1155/2009/201430Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s DiseaseDaniel C Sadowski0Charles N Bernstein1Alain Bitton2Ken Croitoru3Richard N Fedorak4Anne Griffiths5the CAG Crohn’s Consensus GroupRoyal Alexandra Hospital, Edmonton, Alberta, CanadaUniversity of Manitoba, Winnipeg, Manitoba, CanadaMcGill University, Montreal, Quebec, CanadaUniversity of Toronto, Toronto, Ontario, CanadaUniversity of Alberta, Edmonton, Alberta, CanadaUniversity of Toronto, Toronto, Ontario, CanadaBACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published by the Canadian Association of Gastroenterology in 2004. However, recent clinical findings and drug developments warrant a review and update of these guidelines.http://dx.doi.org/10.1155/2009/201430 |
| spellingShingle | Daniel C Sadowski Charles N Bernstein Alain Bitton Ken Croitoru Richard N Fedorak Anne Griffiths the CAG Crohn’s Consensus Group Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease Canadian Journal of Gastroenterology |
| title | Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease |
| title_full | Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease |
| title_fullStr | Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease |
| title_full_unstemmed | Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease |
| title_short | Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease |
| title_sort | canadian association of gastroenterology clinical practice guidelines the use of tumour necrosis factor alpha antagonist therapy in crohn s disease |
| url | http://dx.doi.org/10.1155/2009/201430 |
| work_keys_str_mv | AT danielcsadowski canadianassociationofgastroenterologyclinicalpracticeguidelinestheuseoftumournecrosisfactoralphaantagonisttherapyincrohnsdisease AT charlesnbernstein canadianassociationofgastroenterologyclinicalpracticeguidelinestheuseoftumournecrosisfactoralphaantagonisttherapyincrohnsdisease AT alainbitton canadianassociationofgastroenterologyclinicalpracticeguidelinestheuseoftumournecrosisfactoralphaantagonisttherapyincrohnsdisease AT kencroitoru canadianassociationofgastroenterologyclinicalpracticeguidelinestheuseoftumournecrosisfactoralphaantagonisttherapyincrohnsdisease AT richardnfedorak canadianassociationofgastroenterologyclinicalpracticeguidelinestheuseoftumournecrosisfactoralphaantagonisttherapyincrohnsdisease AT annegriffiths canadianassociationofgastroenterologyclinicalpracticeguidelinestheuseoftumournecrosisfactoralphaantagonisttherapyincrohnsdisease AT thecagcrohnsconsensusgroup canadianassociationofgastroenterologyclinicalpracticeguidelinestheuseoftumournecrosisfactoralphaantagonisttherapyincrohnsdisease |